CMS Colorectal Cancer Drug Coverage Decision Comments Are Due Dec. 31
This article was originally published in The Pink Sheet Daily
Executive Summary
Avastin, Erbitux, Eloxatin and Camptosar clinical trials in off-label uses would be funded under the agency's draft coverage determination. Comments on CMS' draft Medicare drug benefit documents and applications for FDA's continuous marketing Pilot 2 program are also due the last week of December.
You may also be interested in...
CMS To Fund Clinical Trials Evaluating Off-Label Use Of Avastin, Erbitux
Under the agency’s proposed national coverage decision for colorectal therapies, CMS will fund costs of experimental drugs and routine care in nine National Cancer Institute trials. Use of Avastin in patients with colorectal cancer in the adjuvant setting and use of Erbitux in head and neck cancers are among the indications being studied in the NCI trials.
House Appropriations Subcommittee Plans FDA Hearing July 26
Ag/FDA subcommittee had tabled FDA hearing pending confirmation of a permanent agency commissioner. House cleared FDA 2006 spending in early June.
Second Quarter Earnings Season Heats Up
Amgen, J&J, Sanofi-Aventis, Pfizer, Merck, Roche, Lilly and Schering-Plough are scheduled to report results in upcoming week. Bristol could expand upon plans to sell OTC unit to Novartis the following week.